Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

When ubiquitin meets NF-κB: a trove for anti-cancer drug development.

Wu ZH, Shi Y.

Curr Pharm Des. 2013;19(18):3263-75. Review.

2.

Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.

Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT, Van Waes C.

Mol Cancer Ther. 2008 Jul;7(7):1949-60. doi: 10.1158/1535-7163.MCT-07-2046.

3.

Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.

Jia L, Gopinathan G, Sukumar JT, Gribben JG.

PLoS One. 2012;7(2):e32584. doi: 10.1371/journal.pone.0032584. Epub 2012 Feb 29.

4.

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.

Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S.

Mol Cancer. 2008 May 19;7:40. doi: 10.1186/1476-4598-7-40.

5.

NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.

Amschler K, Schön MP, Pletz N, Wallbrecht K, Erpenbeck L, Schön M.

J Invest Dermatol. 2010 Apr;130(4):1073-86. doi: 10.1038/jid.2009.365. Epub 2009 Nov 26.

6.

Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.

Mitsiades CS.

J Clin Oncol. 2015 Mar 1;33(7):782-5. doi: 10.1200/JCO.2014.55.5748. Epub 2015 Jan 20. No abstract available.

7.

Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.

Nakata W, Hayakawa Y, Nakagawa H, Sakamoto K, Kinoshita H, Takahashi R, Hirata Y, Maeda S, Koike K.

Int J Oncol. 2011 Dec;39(6):1529-36. doi: 10.3892/ijo.2011.1141. Epub 2011 Jul 22.

PMID:
21785822
8.

The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.

Cvek B, Dvorak Z.

Curr Pharm Des. 2011;17(15):1483-99. Review.

PMID:
21504411
9.

Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.

Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C.

Clin Cancer Res. 2008 Jul 1;14(13):4175-85. doi: 10.1158/1078-0432.CCR-07-4470.

10.

The role of proteasome in malignant diseases.

Moran E, Nencioni A.

J BUON. 2007 Sep;12 Suppl 1:S95-9. Review.

PMID:
17935285
11.

Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.

Tsapakidis K, Vlachostergios PJ, Voutsadakis IA, Befani CD, Patrikidou A, Hatzidaki E, Daliani DD, Moutzouris G, Liakos P, Papandreou CN.

Int J Urol. 2012 Jun;19(6):565-74. doi: 10.1111/j.1442-2042.2012.02967.x. Epub 2012 Feb 10.

12.

Novel proteasome inhibitors to overcome bortezomib resistance.

Ruschak AM, Slassi M, Kay LE, Schimmer AD.

J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17. doi: 10.1093/jnci/djr160. Epub 2011 May 23. Review.

PMID:
21606441
13.

Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.

Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N.

J Clin Endocrinol Metab. 2006 Oct;91(10):4013-21. Epub 2006 Jul 18.

PMID:
16849420
14.

The significance of ubiquitin proteasome pathway in cancer development.

Yerlikaya A, Yöntem M.

Recent Pat Anticancer Drug Discov. 2013 Sep;8(3):298-309. Review.

PMID:
23061719
15.

Melatonin as a proteasome inhibitor. Is there any clinical evidence?

Vriend J, Reiter RJ.

Life Sci. 2014 Oct 12;115(1-2):8-14. doi: 10.1016/j.lfs.2014.08.024. Epub 2014 Sep 16. Review.

PMID:
25219883
16.

Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.

Soucy TA, Smith PG, Rolfe M.

Clin Cancer Res. 2009 Jun 15;15(12):3912-6. doi: 10.1158/1078-0432.CCR-09-0343. Epub 2009 Jun 9.

17.

Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.

Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.

J Nucl Med. 2012 Nov;53(11):1764-71. doi: 10.2967/jnumed.111.101295. Epub 2012 Oct 10.

18.

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G.

Blood. 2008 Mar 1;111(5):2765-75. Epub 2007 Dec 5.

19.

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.

Denlinger CE, Rundall BK, Keller MD, Jones DR.

Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14.

PMID:
15464472

Supplemental Content

Support Center